Research Study on Comfort of the New FLUME Catheter to Begin Recruitment
The Flume Catheter Company Ltd. (TFCC), a medical device company dedicated to developing an improved alternative to the Foley indwelling urinary catheter, announced the launch of a study to gather real-world data on patient experiences with the new FLUME catheter.
Duke-led consortium envisions new plan for organ transplant management
While organ transplantation is one of the true modern miracles of healthcare, oversight of the U.S. national system regulating and governing solid organ transplantation has been criticized on multiple levels. Ultimately, an overhaul is needed to grow the number of organ transplants, reduce waste, eliminate inequities, and usher in a state-of-the-art information system.
Sixth Pharmaceutical Company Joins the CardioHealth Alliance, Further Expanding Reach and Impact of Evidence-Based Prevention and Care
CardioHealth Alliance welcomed Novo Nordisk Inc. to the CardioHealth Alliance group on March 9, 2023, aiming to expedite evidence-based solutions for prevention and care of cardiovascular, renal and metabolic cardio-metabolic diseases.
DCRI HEAL Connections Team Assembles Naloxone Kits at Team Building Event
The HEAL Connections team – led by DCRI faculty Asheley Skinner, PhD (Population Health) and Rachel Greenberg, MD, MB, MHS, and Christoph Hornik, MD, PhD, MPH (Pediatrics) – partnered with the North Carolina Harm Reduction Coalition (NCHRC) to make naloxone kits on March 21 as an opportunity to connect in-person and learn more about community efforts to stop overdose deaths.
DCRI Releases 2022 Impact Report
At the DCRI, we’re bringing creative solutions to the world’s most vexing health problems.
Boehringer Ingelheim and Eli Lilly and Company Join CardioHealth Alliance
A consortium called the CardioHealth Alliance brings together a multi-disciplinary group of experts to improve the care and health of patients across cardiovascular, renal and metabolic diseases.
Laos, Malawi, Rwanda and Zambia Receive Oral Antiviral Treatments for High-Risk Patients Through COVID Treatment Quick Start Consortium
The COVID Treatment Quick Start Consortium announced today that the governments of Zambia, Laos, Malawi and Rwanda have received shipments of PAXLOVID™ (nirmatrelvir/ritonavir), Pfizer’s COVID-19 oral treatment. Partners involved in the Quick Start Consortium are supporting test-and-treat programs to improve access to antiviral treatments in low- and middle-income countries.
DCRI Highlights From ACC.23 Together With WCC
DCRI faculty and staff took part in more than 80 events at the 2023 American College of Cardiology Scientific Sessions (ACC.23), paired together with the World Congress of Cardiology (WCC). Events included late-breaking and featured presentations, panel discussions, debates, mentorship events, and moderated poster sessions. They covered topics ranging from interventional therapies, drug comparisons, and health equity research, to guideline adherence and preventive care.
Intervention Helps Clinicians Meet Guidelines for Prescribing Diabetes, Heart Drugs
Patients who have diabetes and heart disease do best when both conditions are treated according to established guidelines, but far too many are not prescribed the effective therapies. A recent study — designed and led by the Duke Clinical Research Institute (DCRI) and an academic steering committee — found that a coordinated care approach between cardiologists and diabetes specialists resulted in more patients receiving the recommended therapies. The study was funded by Boehringer Ingelheim and Eli Lilly and Company.
‘Don’t Miss a Beat’: DCRI’s Greene joins Brigham and Women’s Vaduganathan in monthly cardiology research podcast
Duke Clinical Research Institute cardiovascular faculty member Stephen Greene, MD, joins Brigham and Women’s cardi